BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15251394)

  • 1. Prevention of murine acute graft-versus-host disease by recipient-derived TGFbeta1-treated dendritic cells.
    Mou HB; Lin MF; Cen H; Huang H; Cai Z
    Transplant Proc; 2004 Jun; 36(5):1604-6. PubMed ID: 15251394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of murine acute graft-versus-host disease by recipient-derived paired immunoglobulin-like receptor B lentivirus-transfected dendritic cells.
    Zhao J; Luo Y; Wang X; Zhou H; Li Q; You Y; Zou P
    Acta Haematol; 2010; 124(3):134-40. PubMed ID: 20881379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of third-party tolerogenic dendritic cells in the prevention of acute graft-versus-host-disease following allogeneic bone marrow transplantation in mice].
    Li GP; Yang J; Hao J; Yang YM; Ren YN; Xie RF; Fan HH; Qian KC
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):461-6. PubMed ID: 22967381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid lethality of hosts by interleukin-12 following H-2 compatible allogeneic bone marrow transplantation: Reminiscence of gut-associated acute graft-versus-host reaction.
    Schmitt M; Taniguchi M; Yoshida T; Miyahara Y; Gu X; Mukai K; Yagita H; Dohner H; Shiku H
    Int J Oncol; 2002 Oct; 21(4):795-801. PubMed ID: 12239618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of alloreactive natural killer cell in mouse MHC haploidentical bone marrow transplantation].
    He Y; Wang HH; Wang M; Zhou Z; Zhai WJ; Huang Y; Jiang EL; Wang ZD; Zhou SY; Liu QG; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):82-6. PubMed ID: 16732957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects.
    Moyer JS; Maine G; Mulé JJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1010-9. PubMed ID: 17084367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of transforming growth factor beta1 on dendritic cells function].
    Lin MF; Mou HB; Cen H
    Zhonghua Xue Ye Xue Za Zhi; 2004 Aug; 25(8):449-52. PubMed ID: 15555257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy in induction of increased renal allograft survival after portal vein infusion of dendritic cells transduced to express TGFbeta and IL-10, along with administration of CHO cells expressing the regulatory molecule OX-2.
    Gorczynski RM; Bransom J; Cattral M; Huang X; Lei J; Xiaorong L; Min WP; Wan Y; Gauldie J
    Clin Immunol; 2000 Jun; 95(3):182-9. PubMed ID: 10866124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experimental study on immunotherapy with dendritic cell in leukemic mice model].
    Li XX; Chen XL; Ma DX; Liu CS; He XP
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):73-7. PubMed ID: 16732955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells.
    Roelen DL; Schuurhuis DH; van den Boogaardt DE; Koekkoek K; van Miert PP; van Schip JJ; Laban S; Rea D; Melief CJ; Offringa R; Ossendorp F; Claas FH
    Transplantation; 2003 Dec; 76(11):1608-15. PubMed ID: 14702533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of TJU103 in prevention of graft-versus-host disease after allogeneic stem cell transplantation in mice].
    Wang SB; Guo KY; Hu DM; Yin B
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):810-3. PubMed ID: 16793606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third-party tolerogenic dendritic cells reduce allo-reactivity in vitro and ameliorate the severity of acute graft-versus-host disease in allo-bone marrow transplantation.
    Yang J; Li R; Ren Y; Yang Y; Xie R; Fan H
    Scand J Immunol; 2013 Dec; 78(6):486-96. PubMed ID: 24283771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experimental study of Tripterygium hypoglaucum (level) Hutch on preventing acute graft-versus-host disease in bone marrow transplantation mice].
    Li S; Xu KL; Li ZY; Pan XY; Sun HY; Li DP; Cao J; Du B
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):727-30. PubMed ID: 18457261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells.
    Tang W; Yang Y; Zhang F; Li YC; Zhou R; Wang JX; Zhu YN; Li XY; Yang YF; Zuo JP
    Int Immunopharmacol; 2005 Dec; 5(13-14):1904-13. PubMed ID: 16275625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predominant immature CD8alpha+ dendritic cells prevent graft-vs.-host disease but do not increase the risk of leukemia recurrence.
    Xu L; Duan L; Cao K; Yuan G; Peng Y; Huang X; Xiang P; Li S
    Eur J Haematol; 2007 Mar; 78(3):235-45. PubMed ID: 17253973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.